Table 3 Patient characteristics (OR group, 10 patients)

Age (months), median (Q₁–Q₃)

59.3 (46.6–65.8)

Weight (kg), median (Q₁–Q₃)

17.9 (13.6–23)

Sex, male (%)

5 (50%)

Comorbidity, n (%)

 Prematurity

1 (10%)

Pediatric-adapted ASA-PS score, median (Q₁–Q₃)

2.5 (2–3)

Analgesia and sedation received for induction

 Sevoflurane, n (%)

10 (100%)

 Opioids-fentanyl, n (%), median dose (mcg/kg) (Q₁–Q₃)

4 (40%)

1 (0.8–1.1)

 Opioids-remifentanil, n (%), median dose (mcg/kg) (Q₁–Q₃)

4 (40%)

1.5 (1.5–2.8)^a

 Benzodiazepines, n (%)

0 (0%)

 Propofol, n (%), median dose (mg/kg) (Q₁–Q₃)

10 (100%)

1.9 (1.8–2.5)^a

 Dexmedetomidine, n (%), median dose (mcg/kg) (Q₁–Q₃)

4 (40%)

0.5 (0.4–0.6)

 Ketamine, n (%), dose (mg/kg)

1 (10%)

0.5

Other drugs received before measurement

 Dexamethasone, n (%), median dose (mg/kg) (Q₁–Q₃)

10 (100%)

0.1 (0.1–0.1)

Duration of MV on first measurement (minutes), median (Q₁–Q₃)

7.6 (2.6–12.4)

Maximum ΔPaw_max on first measurement (cmH₂O), median (Q₁–Q₃)

31.3 (28.5–35.5)

Median NME_occl on first measurement (cmH₂O/µV), median (Q₁–Q₃)

3.6 (3.5–4.2)

Hospital length of stay (days), median (Q₁–Q₃)

1.5 (1–2.8)